Relapsed/Refractory Chronic Lymphocytic Leukemia: The Evolving Role of BTK Inhibitors

Did you know that the National Comprehensive Cancer Network (NCCN) guidelines now include an investigational noncovalent BTK inhibitor for the treatment of relapsed/refractory CLL? Credit available for this activity expires: 12/05/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998747?ecd=bdc_podcast_libsyn_mscpedu